Once again, MRI has outrun other modalities as a supplemental tool for screening high-risk women.
A large prospective screening trial from the University of Pennsylvania compared screen-film mammography, digital mammography, whole-breast ultrasound, and contrast-enhanced MRI in a population of 569 asymptomatic women. In this single-center trial, funded by the National Cancer Institute, the definition of high risk included women with a 25% lifetime risk based on genetic testing or Gail or Claus models and those with a history of cancer in the contralateral breast.
Of 95 lesions recommended for biopsy, 11 were malignant (11.6%). Seven of the 11 cancers were seen on only one modality: one with digital mammography and six with MRI alone. No cases were seen on either screen-film mammography or ultrasound alone.
"In our study, MRI detected the highest percentage of clinically occult breast cancers in a high-risk population, more than digital mammography, ultrasound, and screen-film mammography," said RSNA meeting presenter Dr. Lily Kernagis, a fellow in women's imaging at Penn.
Follow-up was carried out for one to three years and revealed no new breast cancer diagnoses. Based on the results and follow-up, multimodality screening had a negative predictive value of 100%, sensitivity of 100%, and specificity of 84.9%.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.